Next Generation Proteomics Highlights

We are excited to announce the appointment of Kristina Beeler, PhD as CBO. She will be leading the company’s global commercial and business development activities for the contract research business. Her key focus will be the market expansion in the US and strengthening the commercial activities to meet the growing demand for proteomics in large-scale clinical studies.

Biognosys’ Limited Proteolysis Mass Spectrometry (LiP-MS) technology uses the power of proteomics to validate drug targets, understand mechanisms of action, and anticipate potential off-target effects. Read more on how proteomics can take the uncertainty out of the drug discovery journey in this Technology Networks article.

Target identification and validation are key challenges in drug discovery. Limited Proteolysis Mass Spectrometry (LiP-MS) is a robust, reliable way to identify on- and off-target binding effects throughout the proteome. Biognosys’ Drug Target Deconvolution service utilizes its unique, patented LiP-MS technology to help optimize and de-risk the drug discovery journey.

Next-generation proteomics can be integrated with clinical outcome data to predict which patients will respond or develop side effects from immunotherapy. The highlights from major oncology conferences about our biomarker discovery research in oncology are covered in this GenomeWeb / Precision Oncology News article.

Next-generation proteomics uncovers blood plasma biomarkers for immunotherapy response and side effects in lung cancer patients. Check out our AACR 2021 virtual poster presentation by Kamil Sklodowski in collaboration with Institut Curie and download the poster from our website.

The Parker Institute for Cancer Immunotherapy (PICI), the winner of last year’s Biognosys Grant Program, presented promising first results of the PRINCE trial. We have worked closely with PICI to reveal proteomic signatures associated with clinical outcomes in metastatic pancreatic cancer patients. Together, we plan to share the results of our proteomic analysis at a future conference.